Mersana Therapeutics (MRSN) Stock Price
$6.73 0.3%
to add to portfolio
AI Score
-
Alternative
5 -
Fundamental
1 -
Technical
2
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Mersana Therapeutics, AI stock picks, stock alerts and much more.
MRSN AI Stock Analysis
AI stock analysis for MRSN is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Mersana Therapeutics (MRSN) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Mersana Therapeutics (MRSN) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Mersana Therapeutics (MRSN), currently trading at $6.73, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About MRSN
-
Mersana Therapeutics, Inc.
-
Symbol
MRSN
-
Market
NASDAQ
-
Industry
Biotechnology
-
Market Cap
33.6M
Similar Stocks
 |
Catalyst Pharmaceuticals CPRX |
$21.28 0.1% |
7 |
 |
Inovio Pharmaceuticals INO |
$1.41 2.1% |
2 |
 |
Moderna MRNA |
$29.39 8.6% |
3 |
 |
Anavex Life Sciences AVXL |
$11.32 1.3% |
5 |
 |
BridgeBio Pharma BBIO |
$47.06 3.2% |
6 |
News
MRSN Alternative Data
Web Traffic
Mersana Therapeutics receives an estimated 4916 monthly visitors to mersana.com.
-
Web Traffic
4916
-
Change from Previous Month
1.2%
-
3 Month Change
4.8%
-
YoY Change
4.8%
Facebook Engagement
Mersana Therapeutics has engaged 1 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
1
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
LinkedIn Followers
13,404 are following Mersana Therapeutics on LinkedIn, up by 0.7% over the last month.
-
LinkedIn Followers
13404
-
Daily Change
0%
-
1 Month Change
0.7%
-
3 Month Change
2.5%
Job Postings
Mersana Therapeutics currenly has an estimated 0 open job postings.
-
Job Postings
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
LinkedIn Employees
According to LinkedIn, Mersana Therapeutics has 131 employees, down by -7.7% over the last month.
-
LinkedIn Employees
131
-
Daily Change
0%
-
1 Month Change
7.7%
-
3 Month Change
17.1%
-
YoY Change
17.1%
Reddit Mentions
Mersana Therapeutics has been mentioned an estimated 1 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
1
-
Daily Change
0%
-
1 Month Change
50%
-
3 Month Change
0%
Business Outlook
According to employee reviews, the business outlook among employees at Mersana Therapeutics is 56 out of 100 (neutral).
-
Business Outlook
56
-
Change from Previous Month
0%
-
3 Month Change
3.7%
-
YoY Change
3.7%
News Mentions
Mersana Therapeutics was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
100%
-
1 Month Change
0%
-
3 Month Change
0%
Twitter Followers
Mersana Therapeutics has 1,492 Twitter Followers on its main Twitter (also known as X) account.
-
Twitter Followers
1492
-
Daily Change
0.1%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
MRSN Financials
MRSN Key Metrics
-
Total Revenue
$16.4M
-
Net Income
-$14.1M
-
Earnings per Share
-$0.11
-
Free cash flow
-$19.3M
-
EBITDA
-$12.8M
-
EBITDA Ratio
-0.783204
-
Total Assets
$144.7M
MRSN 2-year Revenue & Income
MRSN 2-year Free Cash Flow
MRSN Technicals
MRSN SMA
MRSN RSI
FAQ
What's the current price of Mersana Therapeutics (MRSN) Stock?
The price of an Mersana Therapeutics (MRSN) share is $6.73.
What's the market cap of Mersana Therapeutics?
The current market cap of Mersana Therapeutics is 33.6M.
Should I buy or sell MRSN?
Mersana Therapeutics shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Mersana Therapeutics is better viewed as a hold or accumulate position while waiting for further developments.
Is Mersana Therapeutics a good investment?
The current analysis of Mersana Therapeutics' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Mersana Therapeutics' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy Mersana Therapeutics (MRSN) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Mersana Therapeutics stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to Mersana Therapeutics (MRSN) that investors often compare it to?
Mersana Therapeutics (MRSN) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.
What is the forecast for Mersana Therapeutics' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Mersana Therapeutics' stock price to be around $6.51 in 2026. Starting from the current price of $6.73, this represents a 3.3% change in price, indicating a neutral outlook for the stock.
How to buy Mersana Therapeutics (MRSN) Stock?
Mersana Therapeutics stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Mersana Therapeutics shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.